Estimation of treatment effect adjusting for dependent censoring using the IPCW method: An application to a large primary prevention study for coronary events (MEGA study)

Clinical Trials

Volumn 4, Issue 4, 2007, Pages 318-328

  Yoshida, Mizuki ^a   Matsuyama, Yutaka ^b   Ohashi, Yasuo ^b  

^a EPS Corporation   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; METHODOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIMULATION; STROKE; THERAPY EFFECT; TREATMENT OUTCOME;

ACYL COENZYME A; COMPUTER SIMULATION; CORONARY ARTERY DISEASE; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRAVASTATIN; PRIMARY PREVENTION; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 35348922366     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774507081224     Document Type: Article

References (16)

1. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 2004; 68: 860-67.
2. Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155-63.
3. Rubin DB. Inference and missing data. Biometrika 1976; 63: 581-92.
4. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data (2nd ed.) John Wiley, New York, 2002.
5. Robins JM. Information recovery and bias adjustment in proportional hazards regression analysis of randomized trials using surrogate makers. American Statistical Association Proceedings of the Biopharmaceutical Section 1993; 24-33.
6. Robins JM, Rotnitzky A, Zhao LP. Analysis of semi-parametric regression models for repeated outcomes in the presence of missing data. J A Stat Assoc 1995; 90: 106-21.
7. Robins JM, Finkelstein DH. Correcting for non-compliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000; 56: 779-88.
8. Scharfstein DO, Robins JM. Estimation of the failure time distribution in the presence of informative censoring. Biometrika 2002; 89: 617-34.
9. Joffe MM, Hoover DR, Jacobson LP et al. Estimating the effect of zidovudine on kaposi's sarcoma from observational data using a rank preserving structural failure-time model. Stat Med 1998; 17: 1073-102.
10. Robins JM. Causal inference from complex longitudinal data. In Berkane M. Ed). Latent variable modeling and application to causality Springer-Verlag, New York, 69-117, 1997.
11. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
12. Horvitz DG, Thompson DJ. A generalization of sampling without replacement from a finite universe. J A Stat Assoc 1952; 47: 663-85.
13. Satten GA, Datta S. The Kaplan-Meier estimator as an inverse-probability-of-censoring weighted average. The American Statistician 2001; 55: 207-10.
14. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J A Stat Assoc 1989; 84: 1074-78.
15. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-60.
16. Zhang J, Heitjan DF. Nonignorable censoring in randomized clinical trials. Clin Trials 2005; 2: 488-96.